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We report here a compilation of p53 mutation results from two smoking-related cancers, lung
cancer and bladder cancer. The overall mutation frequencies reported for these two types of
cancer were relatively similar-50% in lung cancer and 40% in bladder cancer. The compiled data
from lung cancer and bladder cancer suggest an increasing proportion of patients with p53
mutations in nonsmokers, former smokers, and current smokers, in that order, in both cancer
groups. Taken together, more than half (55% and 56% for lung cancer and bladder cancer,
respectively) of the patients who continued smoking (CS), less than 40% (38% and 38%) of
those who had stopped smoking before (.1 or .5 years) clinical diagnosis (ES), and less than
30% (25% and 29%) of those who were nonsmokers (NS) had a p53 mutation. The differences
seen in the mutation frequencies between the three smoking groups did not, however, reach
statistical significance (lung cancer-CS vs ES: odds ratio [OR] =2.0, 95% Cl 0.7-5.4; CS vs NS:
OR=3.7, 95% Cl 0.4-37; bladder cancer-CS vs ES: OR=2.1, 95% Cl 0.6-7.9; CS vs NS:
OR=3.1, 95% Cl 0.7-13). Guanine to thymine transversions were the most common type in
lung cancer followed by guanine to adenine transitions. In bladder cancer, on the contrary, G:C to
A:T transitions at cytosine-guanine dinucleotide sites were the most frequently detected base
substitutions. Analysis of the compiled p53 mutation data suggests that, in addition to lifetime
cumulative exposure to cigarette smoke, also stopping smoking for years prior to clinical manifes-
tation of the disease may affect the incidence of p53 mutations. The differences in the mutation
profiles appear to support the view that the main genotoxic agents from cigarette smoke exposure
may be different in bladder cancer as compared to lung cancer, as suggested previously by DNA
adduct studies. Environ Health Perspect 104(Suppl 3):553-556 (1996)
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Introduction
The concept ofmolecular cancer epidemi-
ology covers integration ofdata obtained
using molecular biological methods (bio-
markers) into studies on human cancer
risk. The ultimate aim ofthis approach is
improved resolution for cancer prevention.
Mutations induced by a certain chemical
exposure are applicable as representative
markers or fingerprints ofthe agent (i.e.,
putative end points for biomarker studies).
A growing body ofevidence suggests that
mutations found in crucial cancer-related
target genes in clinically manifested neo-
plasms may, even if seen in such a late
stage ofthe tumorigenesis process, reveal
clues from the exposure(s) associated with
the development ofthe disease (1-4).
Epidemiological studies have indicated
that cancers ofthe lungand urinary bladder
are both strongly associated with cigarette
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smoking. It is estimated that, in men, 80 to
90% of lung cancers and 40 to 50% of
bladder cancers are attributable to tobacco
smoking (5,6). In a recent study on squa-
mous cell carcinoma ofthe head and neck,
a high frequency ofmutations ofthe p53
tumor suppressor gene were linked to
tobacco smoking and alcohol use (7). The
p53 mutation pattern has been demon-
strated to be different in environmental
cancers, including many tobacco-related
cancers, as compared to other types of
cancers (8).
We have recently completed analysis of
the frequency and pattern ofp53 mutation
from patients with lung cancer, mainly of
squamous cell carcinoma or adenocarci-
noma type (9), and from patients with
transitional cell carcinoma ofthe bladder
(10). The majority of the patients were
cigarette smokers. Despite the same main
etiological background, it is generally
postulated that the carcinogens/mutagens
from tobacco smoke responsible for DNA
damage in the two target organs are, at
least in part, different. We therefore sought
to receive more information on possible
tissue specificity ofsmoking-related muta-
genesis/carcinogenesis by contrasting
molecular analysis ofp53 gene from these
two malignancies.
Subjects and Methods
One hundred and three lung tumors were
studied from consecutive patients, mostly
with non-small cell carcinoma (NSCLC),
who attended Helsinki University Central
Hospital for pulmonary resection. Demo-
graphic data, histopathology, and exposure
data ofthe lung cancer patients, as well as
details of the molecular analysis, were
described earlier (9,11). Compilation of
the p53 mutation data from the lung
cancer patients who were current (n=78),
former (n=21, stopped smoking .5 years
prior to operation), or nonsmokers (n=4)
were compared with that from patients
with urinary bladder cancer. Paraffin-
embedded formalin-fixed tumor samples
from 55 patients with transitional cell car-
cinoma (TCC) of the bladder who had
undergone surgery or biopsy at Turku
University Central Hospital were analyzed
for p53 mutation with the same methods
(denaturing gradient gel electrophoresis
[DGGE] and direct sequencing) as the
lung tumor DNA samples (10). Based on
the hospital records, 16 of the patients
with TCC were current smokers, 21 were
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former smokers (stopped smoking > 1 year
prior to the operation), and 17 were non-
smokers. For one case, no data on smoking
were available. Details ofstudy design, his-
topathology, patient exposure histories, and
mutation analysis are given elsewhere (10).
Results
The overall mutation frequency was 50%
among the lung cancer patients and 40%
among the bladder cancer patients (9,10).
When the patients were divided into groups
of nonsmokers, former smokers, and cur-
rent smokers according to their smoking
status, a dear gradient in the mutation fre-
quency was observed, with the highest
amount of mutations in the patients who
had continued smoking (Figure 1).
In lung cancer, one out of four non-
smokers (25%, NS), 8 of21 (38%) former
smokers (ES) and 43 of78 (55%) current
smokers (CS) had a p53 mutation in the
tumor tissue. The differences in the muta-
tion frequencies among the three smoking
groups did not, however, reach statistical
significance (CS vs ES: odds ratio [OR]
=2.0, 95% CI 0.7- 5.4, p = 0.13; CS vs
NS: OR=3.7, 95% CI 0.4-37, p=0.25).
The lung cancer patients considered as for-
mer smokers were those who had stopped
smoking 5 years or more prior to surgery.
They had a mean exposure history ofciga-
rette smoking of40 pack-years (SD =26)
and had refrained from smoking for 17
years (mean; SD = 11). The mean age at
which these former smokers had stopped
smoking was 51 years (SD = 12). The
patients who were currently smoking had
been exposed to cigarette smoke on average
for 44 pack-years (mean, SD =20).
El NS * ES ECS
Lung
cancer
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cancer
Interestingly, the prevalence of muta-
tions found among the bladder cancer
patients is very similar to lung cancer: 5
out of 17 nonsmokers (29%), 8 of 21 ex-
smokers (38%), and 9 of 16 (56%) current
smokers had at least one p53 mutation
(10). The differences between the groups
were statistically nonsignificant (CS vs ES:
OR=2.1, 95% CI, 0.6-7.9, p=0.22; CS vs
NS: OR=3.1, 95% CI, 0.7-13,p=0.1).
For the bladder cancer patients, the smok-
ing status was given by the patient at the
time ofdiagnosis (stopped smoking 1 year
or more before diagnosis) without pack-
year details; these data were obtained from
the hospital records.
Figure 2 shows the comparison ofthe
types ofbase substitutions between these
two malignancies. Guanine to thymine
transversions were, as expected, the most
common type ofbase substitution (33%)
seen in lung cancer, followed by guanine to
adenine transitions (31%) (9). In bladder
cancer, G:C to A:T transitions were the
most frequendy detected base substitutions,
and the second most frequent alteration
was A:T to C:G (10). In this set ofbladder
tumors, no G:C to T:A transversions were
seen. The majority (5/7) ofthe G:C to A:T
mutations detected in bladder cancer were
at CpG sites (10), whereas in lung cancer
only one-fourth (3/12) ofG:C to A:T tran-
sitions had occurred at cytosine-guanine
dinucleotide sites (Figure 2).
Discussion
Here we report compiled results of p53
mutation analysis from two cancers, lung
cancer (9) and bladder cancer (10), with
environmental etiology. The overall muta-
tion frequencies are relatively similar,
although they are somewhat higher in lung
cancer (50%) than in bladder cancer
(40%); both ofthese frequencies are com-
parable to those reported in the literature
(8,12,13). The main recorded source of
43n78
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Figure 1. Frequency of p53 mutations (%) in nonsmok-
ers (NS), former smokers(ES), and current smokers(CS)
among lung cancer and bladder cancer patients. Data
for bladder cancerfrom Kannio et al. (10).
G:C>T:A G:C>A:T G:C>C:G A:T>C:G A:T>G:C A:T>T:A
Figure 2. Comparison of the specific base substitu-
tions detected in lung cancer (n=39) and bladder
cancer (n=14). Data for bladder cancer from Kannio et
al. (10).
exposure is cigarette smoking, although
occupational exposure to asbestos has been
documented for a subset ofpatients in both
cancer groups (10,11). Occupational expo-
sure to asbestos, however, has not been
found to be associated with p53 mutations
in bladder cancer (10), and the preliminary
data from lung cancer also appear to be
negative (Husgafvel-Pursiainen et al., in
preparation). Earlier, we observed a link
that remained statistically nonsignificant
between occupational exposure to asbestos
and mutations in the K-ras gene in lung
adenocarcinoma (14).
In the present study, p53 mutations
have been found to be associated with the
tobacco-exposure status of the patients
with lung cancer and bladder cancer.
Despite the gradient observed for both
cancer types, the associations are not statis-
tically significant, probably due to small
numbers. The compiled data from the two
groups indicate that, on average, more than
halfofthe patients who continued smok-
ing, less than 40% of those who had
stopped smoking before clinical diagnosis,
and less than 30% ofthose who were non-
smokers had a p53 mutation. A previous
study on lung adenocarcinoma found an
increasing proportion ofpatients with p53
overexpression in current smokers versus
former smokers versus nonsmokers (56%
vs 33% vs 0%) (15). These observations of
a decreased frequency ofp53 alterations in
former smokers and nonsmokers, as con-
trasted to smokers, appear to be consistent
with the epidemiological data pointing to a
clear beneficial effect ofstopping smoking,
as seen in cancer mortality for most primary
sites including the lung and bladder (16).
A positive association with smoking
(cancer deaths) has been recently con-
firmed, as well as the association ofsmok-
ing with cancers of the mouth, pharynx,
and larynx (16). A study on the squamous
cell carcinoma ofthe head and neck found
an overall mutation frequency of42% and
a significant dependence of the incidence
of p53 mutations on the use of tobacco
and alcohol (7). In that study, 58% ofthe
patients who smoked cigarettes and used
alcohol, 33% of the patients who smoked
but abstained from alcohol, and 17% of
the patients who neither smoked nor drank
alcohol had p53 mutations. The head and
neck cancer patients classified as smokers
were those who had smoked (at least 20
pack-years) during the 20 years preceding
their treatment for the cancer.
In lung cancer, earlier studies have
suggested a link between cigarette smoking
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and p53 mutations or nuclear overexpres-
sion (17-20). We failed to see a statisti-
cally significant difference in the frequency
ofmutations between lung cancer patients
with more than 40 pack-years ofcigarette
smoking and those with 40 pack-years or
less overall, when stopping smoking was
not taken into account (9). The difficulty
in finding a clear dose dependence between
smoking and lung cancer may, in part, be
explained by the fact that the majority of
lung cancers arise in heavy to moderate
smokers, and consequently, tumors from
lifetime nonsmokers are rarely available for
molecular analysis. The few nonsmoker
cases reported at this time show an overall
level of mutations comparable to, but a
base substitution pattern deviant from, that
in smokers (21). Nuclear overexpression or
mutations have been found in 40 to 45%
of bladder tumors from smokers and at a
lower level (30-35%) among ex-smokers
and nonsmokers in many (12,22) but not
all (23) studies.
It is well known that the patterns of
mutations observed in lung cancer and some
other smoking-related cancers differ from
those in cancers with different etiological
backgrounds (8,24). The specific base sub-
stitution profiles analyzed in this study for
the two cancers appear to reveal differences.
The clearest differences were seen in G:C to
T:A transversions and G:C to A:T transi-
tions. Guanine to thymine transversions
were missing in bladder cancer but were
the most common type in lung cancer.
Secondly, G:C to A:T transitions were the
most frequent type seen in bladder cancer
and typically occurred at cytosine-guanine
dinucleotide (CpG) sites; this has also been
reported in other studies (13,25). It is pos-
tulated that G to A or C to T transitions at
CpG sites can result from various sponta-
neous cellular processes or endogenous
mutagens (8). This could imply a more
prominent role for such endogenous mech-
anisms in bladder carcinogenesis as com-
pared to lung carcinogenesis or a greater
contribution to p53 mutagenesis oftobacco
smoke constituents capable ofpreferentially
inducing this type ofbase substitutions in
bladder tissue than in lung tissue ofsmok-
ers. In lung cancer, G:C to A:T transitions
have been more frequent and G:C to T:A
transversions less frequent in nonsmokers
than in smokers (21). It has been proposed,
that, for bladder cancer related to chronic
urinary infection with Schistosoma haema-
tobium, an excess of transitions at CpG
sites ofthe p53 gene is induced by a mech-
anism involving production of nitric oxide
provoked by inflammation (26).
In this study, we analyzed tumor tissue
samples with similar molecular methods
from two sets ofcancer patients. Therefore,
it is possible that the observed mutation
profiles reflect differences in the types of
predominant mutations rather than just
methodological variation in the molecular
analyses. In bladder cancer, however, the
number of mutations available for the
comparison was relatively small (10).
Literature data on bladder cancer seem,
however, to support our findings (13).
In summary, the present analysis ofthe
compiled p53 mutation data, as well as
data from other studies, appears to support
the view that the main genotoxic agents
from cigarette smoke may be different in
bladder cancer than in lung cancer, as sug-
gested previously by DNA adduct studies
(27,28). The analysis indicates an increas-
ing occurrence ofp53 mutations in non-
smokers, former smokers, and current
smokers, in that order, in both these sets of
cancer patients. The differences in the
mutation frequencies are not, however, sta-
tistically significant. This suggests that, in
addition to lifetime cumulative exposure to
cigarette smoke estimated as pack-years,
stopping smoking for years prior to clinical
manifestation ofthe disease may affect the
incidence ofp53 mutations.
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